Welcome to our dedicated page for Graystone news (Ticker: GYST), a resource for investors and traders seeking the latest updates and insights on Graystone stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Graystone's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Graystone's position in the market.
Graystone Company (OTC: GYST) announced the completion of its Fucoidan Longevity Booster, a key product in its Immune Support, Anti-Inflammatory & Anti-Aging line. Independent research suggests fucoidan may prevent cancer cell growth and enhance immune responses. Unlike traditional Fucoidan, Graystone's nano-formulation promises improved absorption and efficacy. The wellness supplement market is projected to grow to $386.29 billion by 2027, indicating strong future potential for Graystone's offerings.
Graystone Company, Inc. (OTC: GYST) has announced the upcoming launch of its first product, the Fucoidan Longevity Booster, set for July/August 2021. This innovative product features a nano Fucoidan Extract aimed at enhancing absorption and offers various health benefits, including potential anti-inflammatory, anti-cancer, and anti-aging properties. Research from reputable sources suggests fucoidan's efficacy in boosting immune responses and possibly aiding in cancer treatment. The company is finalizing product formulas, which underscores its commitment to the longevity and wellness market.
Graystone Company (OTC: GYST) has completed a reverse merger with NutraGyst, Inc., shifting its focus to developing products in the Fertility and Longevity & Wellness sectors. The company aims to create high-quality, plant-based supplements that are Non-GMO, gluten-free, and lactose-free. Product formulas and packaging are currently being finalized, with an expected launch of the first product in July/August 2021. The merger is part of Graystone's strategy to innovate in the health supplement market.